Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Prof Tredoux turns theories regarding the formation of metals on its head
2013-09-17

 

Prof Marian Tredoux
17 September 2013

The latest research conducted by Prof Marian Tredoux of the Department of Geology, in collaboration with her research assistant Bianca Kennedy and their colleagues in Germany, placed established theories regarding how minerals of the platinum-group of elements are formed, under close scrutiny.

The article on this research of which Prof Tredoux is a co-author – ‘Noble metal nanoclusters and nanoparticles precede mineral formation in magmatic sulphide melts’ – was published in Nature Communications on 6 September 2013. It is an online journal for research of the highest quality in the fields of biological, physical and chemical sciences.

This study found that atoms of platinum and arsenic create nanoclusters, long before the mineral sperrylite can crystallise. Thus, the platinum does not occur as a primary sulphur compound. The research was conducted at the Steinmann Institute of the University of Bonn, Germany, as well as here in Bloemfontein.

Monetary support from Inkaba yeAfrica – a German-South African multidisciplinary and intercultural Earth Science collaborative of the National Research Foundation (NRF) – made this research possible. Studies are now also being conducted on other metals in the precious metal group, specifically palladium, rhodium and ruthenium.

The discovery of the nanoclusters and the combination with arsenic can have far-reaching consequences for the platinum mine industry, if it can be utilised to recover a greater amount of platinum ore and therefore less wastage ending up in mine dumps. This will signify optimal mining of a scarce and valuable metal, one of South Africa’s most important export products.

For Prof Tredoux, the research results also prove thoughts she already had some twenty years ago around the forming of platinum minerals. “Researchers laughed in my face, but the evidence had to wait for the development of technology to prove it.” Young researchers were very excited at recent congresses about the findings, since the new models can bring new insights.

“Chemistry researchers have been talking about platinum element clusters in watery environments for quite a while, but it was thought that these would not appear in magmas (molten rock) due to the high temperatures (>1 000 degrees celsius).”

Prof Tredoux has already delivered lectures at congresses in Scotland, Hungary, Sweden and Italy on this research.

Read the article at: http://www.nature.com/ncomms/2013/130906/ncomms3405/full/ncomms3405.html

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept